Diagnostic Assays for Myeloperoxidase and Myeloperoxidase Deficiency

2014 ◽  
pp. 537-546 ◽  
Author(s):  
William M. Nauseef
Keyword(s):  
Diagnostic Assays ◽  
Myeloperoxidase Deficiency

Hepatitis C Virus Infection: A Brief Review

JMS SKIMS ◽  
2020 ◽  
Vol 23 (1) ◽  
pp. 3-15
Author(s):  
Saleem Kamili ◽  
Hisham Qadri
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Basic Research ◽  
World Health ◽  
Hepatitis C Virus Infection ◽  
Poor Countries ◽  
Diagnostic Assays ◽  
Antiviral Therapies ◽  
Highly Sensitive ◽  
Resource Poor

Hepatitis C, caused by hepatitis C virus (HCV) was originally described as parenterally transmitted non-A non-B hepatitis. Since its discovery in 1989, the field of HCV research has become a shining example of successful translation of basic research wherein in a short of span of just 30 years the virus was discovered, highly sensitive and specific diagnostic assays were developed, epidemiology and clinical characteristics of the disease were well defined and now with the availability of highly efficacious antiviral therapies many countries are already on their way to achieving World Health Organization’s (WHO) elimination targets of hepatitis C by 2030.  However, much work needs to be done to eliminate hepatitis C especially in resource poor countries. Most recent data show an estimated 71 million people are currently infected with HCV worldwide and approximately 400,000 people die each year from causes related to HCV. Of these estimates, more than 13 million HCV infected persons are in India and Pakistan (Figure 1). Despite the availability of a cure for hepatitis C, only 20% of those infected patients have been diagnosed (1). In order to achieve the WHO targets of hepatitis C elimination, concerted efforts will have to made to make affordable and reliable diagnostics available worldwide.

Stepping up detection, response, preparedness and readiness measures for “COVID-19”- A Pandemic

2020 ◽  
Vol 11 (SPL1) ◽  
pp. 1042-1047
Author(s):  
Khushbu Balsara ◽  
Deepankar Shukla
Keyword(s):  
Health Care ◽  
Health Care Workers ◽  
Clinical History ◽  
Frontline Workers ◽  
Diagnostic Assays ◽  
Care Workers ◽  
Short Period ◽  
History Of ◽  
Detection Response ◽  
Care Worker

In a very short period of time, “COVID-19” has seized the consciousness globally by making remarkable changes in our day to day living and has superintended as a public health emergency globally. It has high radar of transmission, affecting an individual at work to frontline workers. The measures and planning for a response plays a key role from drawing up an emergency committee and this follows an equation which broadly deals with epidemiological to clinical history of the patient, management steps from isolation, screening, diagnostic assays for identification and treatment. The application of an organized plan with secure structure aids in better performance, increases efficacy of management and saves time. Also saves time for a health care worker to g through routine levels of channels of administration if already a familiar way of operation is known for such situations. Thus, planning and developing a ‘blueprint of approach’ towards management of patient while facing such situation is a must. This review provides an insight to the measures for detection, response and preparedness of the hospital and health care workers should largely be inclusive of; also highlights the measures to be taken at every step after coming in contact with a positive case of “COVID-19”.

scholarly journals Comparison of nine different commercially available molecular assays for detection of SARS-CoV-2 RNA

2021 ◽  
Author(s):  
Ute Eberle ◽  
◽  
Clara Wimmer ◽  
Ingrid Huber ◽  
Antonie Neubauer-Juric ◽  
...  
Keyword(s):  
Real Time ◽  
Rt Pcr ◽  
Diagnostic Assays ◽  
Molecular Assays ◽  
Pcr Assays ◽  
Laboratory Experiences

AbstractTo face the COVID-19 pandemic, the need for fast and reliable diagnostic assays for the detection of SARS-CoV-2 is immense. We describe our laboratory experiences evaluating nine commercially available real-time RT-PCR assays. We found that assays differed considerably in performance and validation before routine use is mandatory.

Virus-Like Particles as Positive Controls for COVID-19 RT-LAMP Diagnostic Assays

2021 ◽  
Vol 22 (3) ◽  
pp. 1231-1243
Author(s):  
Soo Khim Chan ◽  
Pinyi Du ◽  
Caroline Ignacio ◽  
Sanjay Mehta ◽  
Isabel G. Newton ◽  
...  
Keyword(s):  
Virus Like Particles ◽  
Diagnostic Assays ◽  
Positive Controls

scholarly journals Comparison of Five Serological Assays for the Detection of SARS-CoV-2 Antibodies

Diagnostics ◽  
2021 ◽  
Vol 11 (1) ◽  
pp. 78
Author(s):  
Anja Dörschug ◽  
Julian Schwanbeck ◽  
Andreas Hahn ◽  
Anke Hillebrecht ◽  
Sabine Blaschke ◽  
...  
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Blood Donor ◽  
Immunoglobulin G ◽  
The Other ◽  
Specific Antibodies ◽  
Diagnostic Assays ◽  
Immunoglobulin Class ◽  
Corona Virus ◽  
Immunoglobulin Subclass

Serological assays can contribute to the estimation of population proportions with previous immunologically relevant contact with the Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) virus. In this study, we compared five commercially available diagnostic assays for the diagnostic identification of SARS-CoV-2-specific antibodies. Depending on the assessed immunoglobulin subclass, recorded sensitivity ranged from 17.0% to 81.9% with best results for immunoglobulin G. Specificity with blood donor sera ranged from 90.2% to 100%, with sera from EBV patients it ranged from 84.3% to 100%. Agreement from fair to nearly perfect was recorded depending on the immunoglobulin class between the assays, the with best results being found for immunoglobulin G. Only for this immunoglobulin class was the association between later sample acquisition times (about three weeks after first positive PCR results) and positive serological results in COVID-19 patients confirmed. In conclusion, acceptable and comparable reliability for the assessed immunoglobulin G-specific assays could be shown, while there is still room for improvement regarding the reliability of the assays targeting the other immunoglobulin classes.

State of the art in rapid paper tests for COVID-19 and coronaviruses

2021 ◽  
Author(s):  
Delyan Hristov ◽  
Jose Gomez-Marquez ◽  
Djibril Wade ◽  
Kimberly Hamad-Schifferli
Keyword(s):  
Global Health ◽  
State Of The Art ◽  
Diagnostic Testing ◽  
Diagnostic Assays ◽  
Health Challenge ◽  
Global Health Challenge

The COVID-19 pandemic has let to an unprecedented global health challenge, creating sudden, massive demands for diagnostic testing, treatment, therapies, and vaccines. In particular, the development of diagnostic assays for...

scholarly journals Variation in LOD Across SARS-CoV-2 Assay Systems: Need for Standardization

2020 ◽  
Author(s):  
Youvraj Sohni
Keyword(s):  
Decision Making ◽  
Clinical Decision Making ◽  
Limit Of Detection ◽  
Clinical Decision ◽  
International Standards ◽  
Performance Characteristics ◽  
Clinical Testing ◽  
Factors Affecting ◽  
Diagnostic Assays ◽  
Technology Platforms

Abstract Multiple SARS-CoV-2 emergency use authorization (EUA) tests are being used for clinical testing across various clinical testing laboratories for meeting the diagnostic challenges of the ongoing pandemic. However, cross-assay variations in performance characteristics need to be recognized. A better understanding is needed of the clinical implications of cross-assay variation in performance characteristics, particularly in the limit of detection (LOD) of the SARS-CoV-2 assays used for clinical testing. Herein, a snapshot of the diversity of SARS-CoV-2 EUA analytical assay systems including methodologies, assay designs, and technology platforms is presented. Factors affecting the variations in LOD are discussed. Potential measures that may standardize across the various assay systems are suggested. Development of international standards and reference materials for the establishment of performance characteristics may substantially alleviate potential clinical decision-making challenges. Finally, cross-assay variation in LODs among the diverse SARS-CoV-2 diagnostic assays impacts clinical decision-making with multiple assay systems in use and lack of standardization across platforms. International standards in parallel with continued cross-platform studies and collaborative efforts across pertinent healthcare entities will help mitigate some of the clinical decision-making challenges.

scholarly journals Impact of repeated nasal sampling on detection and quantification of SARS-CoV-2

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Joshua M. Levy ◽  
Jennifer K. Frediani ◽  
Erika A. Tyburski ◽  
Anna Wood ◽  
Janet Figueroa ◽  
...  
Keyword(s):  
Test Performance ◽  
Perceived Risk ◽  
False Negative ◽  
Sample Collection ◽  
Diagnostic Assays ◽  
Negative Findings ◽  
High Concordance ◽  
Repeated Sample ◽  
Multiple Samples ◽  
The Impact

AbstractThe impact of repeated sample collection on COVID-19 test performance is unknown. The FDA and CDC currently recommend the primary collection of diagnostic samples to minimize the perceived risk of false-negative findings. We therefore evaluated the association between repeated sample collection and test performance among 325 symptomatic patients undergoing COVID-19 testing in Atlanta, GA. High concordance was found between consecutively collected mid-turbinate samples with both molecular (n = 74, 100% concordance) and antigen-based (n = 147, 97% concordance, kappa = 0.95, CI = 0.88–1.00) diagnostic assays. Repeated sample collection does not decrease COVID-19 test performance, demonstrating that multiple samples can be collected for assay validation and clinical diagnosis.

Sign in / Sign up

Export Citation Format

Share Document